Y-mAbs Therapeutics

What Y-mAbs Therapeutics does

Y-mAbs Therapeutics was a commercial-stage biopharmaceutical company that developed and commercialized novel antibody-based and radioimmunotherapy products for cancer, anchored by DANYELZA (naxitamab-gqgk) — an anti-GD2 monoclonal antibody approved by the FDA in November 2020 under accelerated approval for pediatric patients (one year and older) and adults with relapsed or refractory high-risk neuroblastoma in bone or bone marrow. The company's underlying technology stack includes the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy (PRIT) platform and the Y-BiClone bispecific antibody platform, both licensed from Memorial Sloan Kettering Cancer Center. Clinical pipeline assets built on SADA include GD2-SADA (Phase 1 in GD2-expressing solid tumors such as small cell lung cancer, melanoma, sarcomas, and adult neuroblastoma) and CD38-SADA (Phase 1 in relapsed/refractory non-Hodgkin Lymphoma).

Y-mAbs generated revenue primarily through direct DANYELZA sales to approximately 70 U.S. treatment centers and through international distribution partners — Nobelpharma (Japan), Adium (Latin America), INPHARMUS (Turkey), and SciClone (Western/Eastern Asia) — supplemented by license and milestone payments. FY2024 total revenue was $87.7 million with a net loss of $29.7 million, and Q1 2025 net product revenue of $20.9 million grew 8% year-over-year. The company held $60.3 million in cash at March 31, 2025, ran two business units (DANYELZA commercial and Radiopharmaceuticals) after a January 2025 reorganization that included a roughly 13% workforce reduction, and was acquired by SERB Pharmaceuticals in September 2025 for approximately $412 million in an all-cash transaction at $8.60 per share.

Name

Y-mAbs Therapeutics

Legal name

Y-mAbs Therapeutics, Inc.

Website

https://ymabs.com

Company type

Public

Founded year

2015

Operating status

Acquired

Headcount range

51–100 employees

Short description

Y-mAbs Therapeutics was a commercial-stage biopharmaceutical company that developed and commercialized DANYELZA, the first FDA-approved anti-GD2 antibody for relapsed or refractory high-risk neuroblastoma, alongside a SADA PRIT radiopharmaceutical pipeline, serving pediatric oncology treatment centers and international distribution partners before being acquired by SERB Pharmaceuticals in September 2025.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Oncology antibody therapeutics
• Radioimmunotherapy platform
• Neuroblastoma treatment
• Pretargeted radiopharmaceuticals
• Bispecific antibody development

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. DANYELZA Product Sales: Net product revenue from commercial sales of DANYELZA (naxitamab-gqgk) in U.S. and international markets. Q1 2025 net product revenues of $20.9 million (8% YoY increase); Full year 2024 net product revenues of $85.2 million. U.S. DANYELZA revenues Q1 2025: $13.4M; Ex-U.S. DANYELZA revenues Q1 2025: $7.5M.
2. License and Distribution Agreements: Upfront payments, milestone payments, and royalty payments from international distribution partners including Nobelphama (Japan - $2M upfront + up to $31M in milestones and royalties), Adium (Latin America), and INPHARMUS (Turkey named patient program). Q4 2024 license revenue of $2M from Nobelphama agreement.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes novel radioimmunotherapy and antibody-based therapeutics for cancer. Its flagship commercial product is DANYELZA (naxitamab-gqgk), an anti-GD2 monoclonal antibody approved for relapsed/refractory high-risk neuroblastoma. The company also advances a pipeline based on its proprietary Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy (PRIT) platform, with candidates GD2-SADA and CD38-SADA in clinical development.

Product overview

Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapies for cancer treatment. The company's portfolio consists of DANYELZA (naxitamab-gqgk), its first FDA-approved anti-GD2 therapy for relapsed/refractory high-risk neuroblastoma, and a pipeline of investigational radiopharmaceutical programs based on its SADA PRIT platform technology. The company operates two business units: DANYELZA (commercial) and Radiopharmaceuticals (pipeline), following its acquisition by SERB Pharmaceuticals in September 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• DANYELZA (naxitamab-gqgk) Anti-GD2 monoclonal antibody indicated in combination with GM-CSF for the treatment of pediatric patients 1 year and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated partial response, minor response, or stable disease to prior therapy. First FDA-approved commercial product for this indication.
• GD2-SADA Bispecific fusion protein that tightly binds to the glycolipid GD2 and Lutetium-177-DOTA, a chelated radionuclide payload. Investigational pretargeted radioimmunotherapy for GD2-expressing solid tumors currently in Phase 1 clinical development.
• CD38-SADA CD38-targeted SADA protein evaluated in Phase 1 clinical trial (Trial 1201) for treatment of relapsed/refractory non-Hodgkin Lymphoma. CD38-SADA protein binds with high affinity to lymphoma cells, followed by administration of radioactive 177Lu-DOTA payload to selectively target tumor cells while minimizing radiation to normal tissues.

Quantifiable outcome

• 50% overall response rate (95% CI: 36-64%) with 38% complete response and 12% partial response in Phase 2 trial
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor, major, core and secondary.

• Convergent TherapeuticsminorOthers · 19 March 2026Michael Rossi, former CEO of Y-mAbs, appointed to Convergent Therapeutics' Board of Directors. Rossi brings over 30 years of radiopharmaceutical industry experience and currently serves as CEO of SHINE SPECT USA.
• National Comprehensive Cancer Network (NCCN)majorOthers · 7 May 2025NCCN updated Clinical Practice Guidelines in Oncology for Neuroblastoma to include naxitamab-gqgk (DANYELZA) as a Category 2A recommended treatment option for high-risk neuroblastoma, providing important clinical guidance recognition.
• Nobelpharma Co. Ltd.coreChannel Partner/ Reseller/ Distributor · 1 October 2024Exclusive license and distribution agreement for development and commercialization of DANYELZA in Japan. Y-mAbs received $2.0M upfront payment in Q4 2024, with up to $31.0M in regulatory-based and sales-based milestone payments plus royalty payments on commercial sales if successfully approved and commercialized in Japan.
• Memorial Sloan Kettering Cancer Center (MSK)coreStrategic or Co-development PartnerResearchers at MSK developed both naxitamab-gqgk (DANYELZA) and SADA technology, exclusively licensed to Y-mAbs. Dr. Nai-Kong Cheung and MSK have institutional financial interests in the compounds and Y-mAbs. MSK received patent acceptance extension for DANYELZA through 2034.
• INPHARMUS (formerly TRPharm)secondaryChannel Partner/ Reseller/ DistributorNamed patient program partner in Turkey for DANYELZA. Continued commercial success with expansion into new markets. TRPharm was formerly known as TRPharm İlaç Sanayi Ticaret A.Ş. and TRPharm FZ-LLC.
• AdiumsecondaryChannel Partner/ Reseller/ DistributorLatin America distribution partner for DANYELZA. License revenue recognized related to price approval for DANYELZA in Brazil from Brazilian Medicines Market Regulation Chamber. Marketing authorization for DANYELZA in Mexico achieved September 2023.
• SciClonesecondaryChannel Partner/ Reseller/ DistributorDistribution partner collaboration for commercial programs in distribution partners' territories. Enhanced collaboration with new commercial programs introduced in distribution partners' territories including Western Asia and Eastern Asia regions.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• United Therapeutics: United Therapeutics markets Unituxin (dinutuximab), the other FDA-approved anti-GD2 monoclonal antibody for high-risk neuroblastoma. Direct competitor in the same indication that Y-mAbs targets with DANYELZA, with comparable patient population and specialty distribution model.
• Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company developing targeted diagnostic and therapeutic agents across oncology (e.g., Illuccix for prostate cancer imaging). Closest comparable in size, business model, and radiopharmaceutical platform approach to Y-mAbs' SADA PRIT ambitions.

Emerging players

• MacroGenics: MacroGenics is a clinical-stage antibody-based oncology company developing therapeutics including enoblituzumab and margetuximab. Comparable to Y-mAbs in size, antibody-platform technology, and oncology focus, though focused on different antigens (HER2, B7-H3).
• Molecular Templates: Molecular Templates is a clinical-stage oncology biotech developing engineered toxin bodies (antibody-based targeted therapies). Similar small-cap profile and antibody-therapeutic platform approach to Y-mAbs, though different mechanism of action.
• Clarity Pharmaceuticals: Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing targeted copper-based diagnostics and therapeutics. Similar emerging-stage profile to Y-mAbs' SADA platform programs, with comparable indication focus in oncology.

Broad incumbents

• Novartis: Novartis commercializes Lutathera and Pluvicto, the two largest-selling radiopharmaceutical therapies. Broad incumbent in the radiopharma space where Y-mAbs' SADA platform competes, with vastly greater clinical, commercial, and capital resources.
• Bayer: Bayer markets Xofigo (radium-223), a radiopharmaceutical therapeutic for prostate cancer, and has broader oncology infrastructure. Broad incumbent competing in the same radiopharmaceutical space where Y-mAbs' SADA platform is positioned.
• Lantheus Holdings: Lantheus is a radiopharmaceutical-focused company with both diagnostic (e.g., Neuraceq, Pylarify) and therapeutic agents. Direct platform overlap with Y-mAbs' SADA pretargeted radioimmunotherapy approach, though Lantheus is larger and more diversified across diagnostic and therapeutic radiopharma.
• Eli Lilly: Eli Lilly acquired POINT Biopharma to enter the radiopharmaceutical space with targeted radioligand therapies. Broad incumbent expanding into the same targeted-radiotherapy category as Y-mAbs' SADA PRIT platform.
• AstraZeneca: AstraZeneca acquired Fusion Pharmaceuticals to enter the targeted radioconjugate space, and has additional oncology infrastructure including approved antibody-drug conjugates. Broad incumbent in the radiopharmaceutical and antibody-therapeutic space where Y-mAbs competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ymabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Y-mAbs Therapeutics